Wall Street analyst estimates for Nuvalent, Inc. (NUVL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-06 | $-1.44 | ||
| 2026-05-07 | $-1.39 | $-1.35 | -3.0% |
| 2026-02-26 | $-1.29 | $-1.48 | +12.8% |
| 2025-10-30 | $-1.70 | $-1.39 | -22.3% |
| 2025-08-07 | $-1.31 | $-1.27 | -3.1% |
| 2025-05-08 | $-1.18 | $-1.14 | -3.5% |
| 2025-02-27 | $-1.05 | $-1.04 | -1.0% |
| 2024-11-12 | $-1.28 | $-0.93 | -37.0% |
Valuation Ratios
| Price / Book | 8.30 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $9.7M | $15.4M | $35.6M | $63.7M | $113.2M | $217.8M | $307.0M |
| Selling, General & Admin | $612000 | $1.5M | $10.3M | $22.4M | $36.2M | $62.6M | $107.3M |
| Operating Expenses | $10.4M | $16.9M | $45.8M | $86.1M | $149.5M | $280.4M | $414.3M |
| Operating Income | -$10.4M | -$16.9M | -$45.8M | -$86.1M | -$149.5M | -$280.4M | -$414.3M |
| EBITDA | -$1.5M | -$16.9M | -$46.1M | -$81.9M | -$126.2M | $20.4M | -$10.5M |
| Interest Expense | 0 | 0 | 0 | 0 | $23.3M | 0 | 0 |
| Pre-tax Income | -$11.8M | -$14.6M | -$46.3M | -$81.9M | -$126.2M | -$260.0M | -$424.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | $764000 | $585000 |
| Net Income | -$11.8M | -$14.6M | -$46.3M | -$81.9M | -$126.2M | -$260.8M | -$425.4M |
| EPS | $-0.24 | $-0.64 | $-2.13 | $-1.65 | $-2.17 | $-3.93 | $-5.85 |
| EPS (Diluted) | $-0.24 | $-0.64 | $-2.13 | $-1.65 | $-2.17 | $-3.93 | $-5.85 |
| Shares Outstanding (Diluted) | $48.3M | $22.9M | $21.8M | $49.7M | $58.2M | $66.4M | $72.7M |
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks